Biogen Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BIIB Nasdaq 2834 www.biogen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biogen Inc.

Biogen Begins Phase III Felzartamab Study for Third Kidney Disease - Jul 1st, 2025 8:50 am
3 Reasons BIIB is Risky and 1 Stock to Buy Instead - Jun 30th, 2025 10:03 pm
AbbVie to buy Capstan for up to $2.1 billion in immunology push - Jun 30th, 2025 6:42 am
RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market - Jun 30th, 2025 6:18 am
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy - Jun 30th, 2025 5:30 am
Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials - Jun 28th, 2025 8:05 am
Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results - Jun 28th, 2025 2:16 am
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA - Jun 27th, 2025 8:00 am
5 Revealing Analyst Questions From Biogen’s Q1 Earnings Call - Jun 26th, 2025 1:46 am
Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations - Jun 25th, 2025 2:46 pm
Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics - Jun 25th, 2025 8:47 am
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results - Jun 25th, 2025 5:31 am
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results - Jun 25th, 2025 5:30 am
Biogen scores Cannes Festival win with dark humored campaign - Jun 24th, 2025 1:36 am
Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia. - Jun 22nd, 2025 11:36 pm
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire - Jun 20th, 2025 2:07 pm
Biogen starts dosing in Phase III trial of Friedreich ataxia therapy - Jun 19th, 2025 5:38 am
21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity - Jun 18th, 2025 9:08 am
H.C. Wainwright sees potential competition for Sage from Biogen - Jun 18th, 2025 7:45 am
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - Jun 18th, 2025 5:30 am